Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial

Journal of Clinical Psychiatry

Volumn 68, Issue 5, 2007, Pages 747-753

  Denys, Damiaan ^a,c   Van Nieuwerburgh, Filip ^b   Deforce, Dieter ^b   Westenberg, Herman G M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b GHENT UNIVERSITY   (Belgium)

^c UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; SEROTONIN; SEROTONIN 1B RECEPTOR; SEROTONIN 2A RECEPTOR; VENLAFAXINE; CYCLOHEXANOL DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG EFFICACY; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MALE; OBSESSIVE COMPULSIVE DISORDER; OUTPATIENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; GENETICS; MIDDLE AGED; PHYSIOLOGY; TREATMENT OUTCOME;

ADULT; CYCLOHEXANOLS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; PAROXETINE; POLYMORPHISM, GENETIC; RECEPTOR, SEROTONIN, 5-HT1B; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 34249738697     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: 10.4088/JCP.v68n0512     Document Type: Article

References (38)

1. Hollander E, Bienstock CA, Koran LM, et al. Refractory obsessive-compulsive disorder: state-of-the-art treatment. J Clin Psychiatry 2002;63(suppl 6):20-29
2. Expert Consensus Guideline Series: Treatment of Obsessive-Compulsive Disorder. J Clin Psychiatry 1997;58(suppl 4):2-72
3. Denys D, Burger H, van Megen H, et al. A score for predicting response to pharmacotherapy in obsessive-compulsive disorder. Int Clin Psychopharmacol 2003;18:315-322
4. Smits KM, Smits LJ, Schouten JS, et al. Influence of SERTPR and STin2 in the serotonin transporter gene on the effect of selective serotonin reuptake inhibitors in depression: a systematic review. Mol Psychiatry 2004;9:433-441
5. McDougle CJ, Epperson CN, Price LH, et al. Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder. Mol Psychiatry 1998;3:270-273
6. Billett EA, Richter MA, King N, et al. Obsessive compulsive disorder, response to serotonin reuptake inhibitors and the serotonin transporter gene. Mol Psychiatry 1997;2:403-406
7. Di Bella D, Erzegovesi S, Cavallini MC, et al. Obsessive-compulsive disorder, 5-HTTLPR polymorphism and treatment response. Pharmacogenomics J 2002;2:176-181
8. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998;59(suppl 20):22-33
9. Goodman WK, Price LH, Rasmussen SA, et al. The Yale-Brown Obsessive Compulsive Scale, 1: development, use, and reliability. Arch Gen Psychiatry 1989;46:1006-1011
10. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62
11. Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50-55
12. Denys D, van der Wee N, van Megen HJ, et al. Double-blind comparison of paroxetine and venlafaxine in obsessive-compulsive disorder. Int J Neuropsychopharmacol 2002;5:131-132
13. Denys D, van Megen HJGM, van der Wee N, et al. A double-blind switch study of paroxetine and venlafaxine in obsessive-compulsive disorder. J Clin Psychiatry 2004;65:37-43
14. Sankoh AJ, Huque MF, Dubey SD. Some comments on frequently used multiple endpoint adjustment methods in clinical trials. Stat Med 1997;16:2529-2542
15. Tatsumi M, Groshan K, Blakely RD, et al. Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol 1997;340:249-258
16. el Mansari M, Bouchard C, Blier P. Alteration of serotonin release in the guinea pig orbito-frontal cortex by selective serotonin reuptake inhibitors: relevance to treatment of obsessive-compulsive disorder. Neuropsychopharmacology 1995;13:117-127
17. Williams RB, Marchuk DA, Gadde KM, et al. Serotonin-related gene polymorphisms and central nervous system serotonin function. Neuropsychopharmacology 2003;28:533-541
18. Smith GS, Lotrich FE, Malhotra AK, et al. Effects of serotonin transporter promoter polymorphisms on serotonin function. Neuropsychopharmacology 2004;29:2226-2234
19. Heinz A, Jones DW, Mazzanti C, et al. A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry 2000;47:643-649
20. van Dyck CH, Malison RT, Staley JK, et al. Central serotonin transporter availability measured with [123I]beta-CIT SPECT in relation to serotonin transporter genotype. Am J Psychiatry 2004;161:525-531
21. Shioe K, Ichimiya T, Suhara T, et al. No association between genotype of the promoter region of serotonin transporter gene and serotonin transporter binding in human brain measured by PET. Synapse 2003;48:184-188
22. Willeit M, Stastny J, Pirker W, et al. No evidence for in vivo regulation of midbrain serotonin transporter availability by serotonin transporter promoter gene polymorphism. Biol Psychiatry 2001;50:8-12
23. Naylor L, Dean B, Pereira A, et al. No association between the serotonin transporter-linked promoter region polymorphism and either schizophrenia or density of the serotonin transporter in human hippocampus. Mol Med 1998;4:671-674
24. Mann JJ, Huang YY, Underwood MD, et al. A serotonin transporter gene promoter polymorphism (5-HTTLPR) and prefrontal cortical binding in major depression and suicide. Arch Gen Psychiatry 2000;57:729-738
25. Tot S, Erdal ME, Yazici K, et al. T102C and -1438 G/A polymorphisms of the 5-HT2A receptor gene in Turkish patients with obsessive-compulsive disorder. Eur Psychiatry 2003;18:249-254
26. Tilakaratne N, Yang Z, Friedman E. Chronic fluoxetine or desmethylimipramine treatment alters 5-HT2 receptor mediated c-fos gene expression. Eur J Pharmacol 1995;290:263-266
27. Li Q, Muma NA, Battaglia G, et al. Fluoxetine gradually increases [125I]DOI-labelled 5-HT2A/2C receptors in the hypothalamus without changing the levels of Gq- and G11-proteins. Brain Res 1997;775:225-228
28. Meyer JH, Kapur S, Eisfeld B, et al. The effect of paroxetine on 5-HT(2A) receptors in depression: an [(18)F]setoperone PET imaging study. Am J Psychiatry 2001;158:78-85
29. Massou JM, Trichard C, Attar-Levy D, et al. Frontal 5-HT2A receptors studied in depressive patients during chronic treatment by selective serotonin reuptake inhibitors. Psychopharmacology (Berl) 1997;133:99-101
30. Sato K, Yoshida K, Takahashi H, et al. Association between -1438G/A promoter polymorphism in the 5-HT(2A) receptor gene and fluvoxamine response in Japanese patients with major depressive disorder. Neuropsychobiology 2002;46:136-140
31. Choi MJ, Lee HJ, Lee HJ, et al. Association between major depressive disorder and the -1438A/G polymorphism of the serotonin 2A receptor gene. Neuropsychobiology 2004;49:38-41
32. Veenstra-VanderWeele J, Anderson GM, Cook EH Jr. Pharmacogenetics and the serotonin system: initial studies and future directions. Eur J Pharmacol 2000;410:165-181
33. Spurlock G, Heils A, Holmans P, et al. A family based association study of T102C polymorphism in 5HT2A and schizophrenia plus identification of new polymorphisms in the promoter. Mol Psychiatry 1998;3:42-49
34. Turecki G, Briere R, Dewar K, et al. Prediction of level of serotonin 2A receptor binding by serotonin receptor 2A genetic variation in postmortem brain samples from subjects who did or did not commit suicide. Am J Psychiatry 1999;156:1456-1458
35. Bray NJ, Buckland PR, Hall H, et al. The serotonin-2A receptor gene locus does not contain common polymorphism affecting mRNA levels in adult brain. Mol Psychiatry 2004;9:109-114
36. Chen Z, Waimey K, Van de Kar LD, et al. Prenatal cocaine exposure potentiates paroxetine-induced desensitization of 5-HT2A receptor function in adult male rat offspring. Neuropharmacology 2004;46:942-953
37. Rioux A, Fabre V, Lesch KP, et al. Adaptive changes of serotonin 5-HT2A receptors in mice lacking the serotonin transporter. Neurosci Lett 1999;262:113-116
38. Hu XZ, Lipsky RH, Zhu G, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 2006;78:815-826